Friday, June 28, 2024 CRC6: Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance) Nowak JA, Twombly T, Ma C, Shi Q, Haruki K, Fujiyoshi K, Väyrynen J, Zhao M, Knight J, Mane S, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, Philip P, O'Reilly EM, Shields AF, Ogino S, Fuchs CS, Meyerhardt JA. Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance) (ONLINE). Journal of Clinical Oncology JCO. 23.01680. 2024.https://ascopubs.org/doi/abs/10.1200/JCO.23.01680 Investigators found that patients with stage III colon cancer whose tumors had PIK3CA gain-of-function mutations experienced improved DFS and OS when treated with adjuvant celecoxib along with standard chemotherapy in a randomized controlled trial.
